Picard Medical PMI
NYSE PMI
$4.15 -0.30 (-6.74%)
As of: Sep 30, 2026 · 3:59 PM EDT

Picard Medical (PMI) Common Equity (2024 - 2026)

Updated

Picard Medical's Common Equity was $1.72 million in Q2 2026, compared with -$54.49 million a year earlier.

Analysis

Picard Medical (PMI) Common Equity (2024 - 2026) Analysis & Trends

At the end of FY2025, Common Equity at Picard Medical came in at $3.8 million.

  • In earlier years, Common Equity was -$44 million in FY2024.
  • Quarterly Common Equity has moved between -$54.49 million (Q2 2025) and $7.97 million (Q3 2025) over five years.
  • Per Business Quant data, PMI's Common Equity in the three quarters before Q2 2026 was -$1.45 million (Q1 2026), $3.8 million (Q4 2025) and $7.97 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Thermo Fisher Scientific 251.30 Bn 230.45 Bn 4.88 Bn 52.69 Bn
2 Abbott Laboratories 174.70 Bn 145.78 Bn 7.27 Bn 51.76 Bn
3 Danaher 158.94 Bn 142.76 Bn 3.61 Bn 52.59 Bn
4 Intuitive Surgical 145.87 Bn 125.42 Bn 1.96 Bn 18.30 Bn
5 Medtronic 111.49 Bn 77.36 Bn 6.34 Bn 50.85 Bn
6 Stryker 106.96 Bn 93.08 Bn 4.50 Bn 23.99 Bn
7 Boston Scientific 63.62 Bn 58.63 Bn 3.85 Bn 25.17 Bn
8 Edwards Lifesciences 50.80 Bn 34.92 Bn 1.35 Bn 10.72 Bn
9 Becton Dickinson 49.59 Bn 46.74 Bn 2.32 Bn 24.42 Bn
10 Picard Medical 9.29 Mn 9.29 Mn 616,000.00 1.72 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.72 Mn
Mar 31, 2026 -1.45 Mn
Dec 31, 2025 3.80 Mn
Sep 30, 2025 7.97 Mn
Jun 30, 2025 -54.49 Mn
Mar 31, 2025 -48.92 Mn
Dec 31, 2024 -44.00 Mn
Sep 30, 2024 -35.40 Mn
Jun 30, 2024 -29.64 Mn
API Access

Picard Medical Common Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=common-equity&ticker=PMI&period=max&api_key=YOUR_API_KEY